Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent.

This report presents the synthesis and evaluation of (111)In(DOTA-6G-RGD(4)) (DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid; 6G-RGD(4) = E{G(3)-E[G(3)-c(RGDfK)](2)}(2) and G(3) = Gly-Gly-Gly), (111)In(DOTA-RGD(4)) (RGD(4) = E{E[c(RGDfK)](2)}(2)) and (111)In(DOTA-3G-RGD(2)) (3G-RGD(2) = G(3)-E[G(3)-c(RGDfK)](2)) as new radiotracers for imaging integrin alpha(v)beta(3)-positive tumors. The IC(50) values of DOTA-6G-RGD(4), DOTA-RGD(4), and DOTA-3G-RGD(2) were determined to be 0.4 +/- 0.1, 1.4 +/- 0.1 and 1.1 +/- 0.1 nM against (125)I-c(RGDyK) bound to integrin alpha(v)beta(3)-positive U87MG human glioma cells. (111)In(DOTA-6G-RGD(4)), (111)In(DOTA-RGD(4)), and (111)In(DOTA-3G-RGD(2)) were prepared by reacting (111)InCl(3) with the respective DOTA conjugate in NH(4)OAc buffer (100 mM, pH = 5.5). Radiolabeling could be completed by heating the reaction mixture at 100 degrees C for 15-20 min. The specific activity was approximately 1850 MBq/micromol for (111)In(DOTA-3G-RGD(2)) and approximately 1480 MBq/micromol for (111)In(DOTA-6G-RGD(4)). The athymic nude mice bearing U87MG human glioma xenografts were used to evaluate tumor uptake and excretion kinetics of (111)In(DOTA-6G-RGD(4)), (111)In(DOTA-RGD(4)), and (111)In(DOTA-3G-RGD(2)). The results from both the integrin alpha(v)beta(3) binding assay and biodistribution studies suggest that the tetrameric cyclic RGD peptides, such as RGD(4) and 6G-RGD(4), are most likely bivalent in binding to the integrin alpha(v)beta(3). Both (111)In(DOTA-6G-RGD(4)) and (111)In(DOTA-RGD(4)) had significantly higher tumor uptake than (111)In(DOTA-3G-RGD(2)) at 24-72 h postinjection due to the extra RGD motifs in RGD(4) and 6G-RGD(4). (111)In(DOTA-3G-RGD(2)) had very little metabolism, while (111)In(DOTA-6G-RGD(4)) had significant metabolism during its excretion via both renal and hepatobiliary routes over the 2 h period, probably due to its much larger size. The combination of high tumor uptake with long tumor retention suggests that their corresponding (90)Y and (177)Lu analogues M(DOTA-6G-RGD(4)) (M = (90)Y and (177)Lu) might be useful as therapeutic radiotracers for treatment of integrin alpha(v)beta(3)-positive solid tumors.

[1]  2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers: effect of technetium chelate on tumor uptake and pharmacokinetics. , 2009, Bioconjugate chemistry.

[2]  Fan Wang,et al.  99mTcO(MAG2-3G3-dimer): a new integrin αvβ3-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  Young-Seung Kim,et al.  Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers. , 2009, Bioconjugate chemistry.

[4]  Fan Wang,et al.  Noninvasive imaging of tumor integrin expression using 18F-labeled RGD dimer peptide with PEG4 linkers , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  Shuangxi Liu.  Radiolabeled Cyclic RGD Peptides as Integrin α v β 3 -Targeted Radiotracers: Maximizing Binding Affinity via Bivalency , 2009 .

[6]  Young-Seung Kim,et al.  Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers. , 2009, Molecular pharmaceutics.

[7]  Fan Wang,et al.  68Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin αvβ3 PET imaging , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  Young-Seung Kim,et al.  Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. , 2008, Journal of medicinal chemistry.

[9]  Weibo Cai,et al.  Imaging of integrins as biomarkers for tumor angiogenesis. , 2008, Current pharmaceutical design.

[10]  Weibo Cai,et al.  Multimodality Molecular Imaging of Tumor Angiogenesis , 2008, Journal of Nuclear Medicine.

[11]  Shuang Liu,et al.  99mTc-labeling of HYNIC-conjugated cyclic RGDfK dimer and tetramer using EDDA as coligand. , 2008, Bioconjugate chemistry.

[12]  Fan Wang,et al.  Linker effects on biological properties of 111In-labeled DTPA conjugates of a cyclic RGDfK dimer. , 2008, Bioconjugate chemistry.

[13]  Xiaoyuan Chen,et al.  Has Molecular and Cellular Imaging Enhanced Drug Discovery and Drug Development? , 2008, Drugs in R&D.

[14]  Shuang Liu,et al.  Coligand effects on the solution stability, biodistribution and metabolism of the (99m)Tc-labeled cyclic RGDfK tetramer. , 2008, Nuclear medicine and biology.

[15]  Xiaoyuan Chen,et al.  68Ga-labeled multimeric RGD peptides for microPET imaging of integrin αvβ3 expression , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  W. Cai,et al.  microPET of Tumor Integrin αvβ3 Expression Using 18F-Labeled PEGylated Tetrameric RGD Peptide (18F-FPRGD4) , 2007, Journal of Nuclear Medicine.

[17]  Young-Seung Kim,et al.  Evaluation of a 99mTc-Labeled Cyclic RGD Tetramer for Noninvasive Imaging Integrin αvβ3-Positive Breast Cancer , 2007 .

[18]  W. Oyen,et al.  Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide. , 2007, Nuclear medicine and biology.

[19]  W. Oyen,et al.  Improved targeting of the αvβ3 integrin by multimerisation of RGD peptides , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  Shuang Liu,et al.  Impact of PKM linkers on biodistribution characteristics of the 99mTc-labeled cyclic RGDfK dimer. , 2006, Bioconjugate chemistry.

[21]  Sanjiv S. Gambhir,et al.  How molecular imaging is speeding up antiangiogenic drug development , 2006, Molecular Cancer Therapeutics.

[22]  Shuang Liu.  Radiolabeled Multimeric Cyclic RGD Peptides as Integrin αvβ3 Targeted Radiotracers for Tumor Imaging , 2006 .

[23]  Bing Jia,et al.  99mTc-Labeled Cyclic RGDfK Dimer: Initial Evaluation for SPECT Imaging of Glioma Integrin αvβ3 Expression , 2006 .

[24]  Xiaoyuan Chen.  Multimodality imaging of tumor integrin alphavbeta3 expression. , 2006, Mini reviews in medicinal chemistry.

[25]  S. Gambhir,et al.  Quantitative PET Imaging of Tumor Integrin αvβ3 Expression with 18F-FRGD2 , 2006 .

[26]  S. Mohammed,et al.  Effect of coligands on biodistribution characteristics of ternary ligand 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer. , 2005, Bioconjugate chemistry.

[27]  S. Gambhir,et al.  microPET Imaging of Glioma Integrin αvβ3 Expression Using 64Cu-Labeled Tetrameric RGD Peptide , 2005 .

[28]  Ryan Park,et al.  MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[29]  R. Haubner,et al.  Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. , 2004, Current pharmaceutical design.

[30]  Ryan Park,et al.  Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide. , 2004, Molecular imaging.

[31]  M. Schwaiger,et al.  Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation , 2004 .

[32]  Horst Kessler,et al.  Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. , 2003, Chemistry.

[33]  S. Robinson,et al.  Integrin alphavbeta3 directed radiopharmaceuticals for tumor imaging , 2003 .

[34]  W. Oyen,et al.  Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. , 2002, Cancer biotherapy & radiopharmaceuticals.

[35]  S. Libutti,et al.  Molecular imaging of tumor angiogenesis , 2002, Journal of cellular biochemistry. Supplement.

[36]  M. Rajopadhye,et al.  (90)Y and (177)Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy. , 2001, Bioconjugate chemistry.

[37]  J. Barrett,et al.  99mTc-labeling of a hydrazinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors. , 2001, Bioconjugate chemistry.

[38]  M Schwaiger,et al.  Tumor angiogenesis targeting using imaging agents. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[39]  R K Jain,et al.  Transport of molecules in the tumor interstitium: a review. , 1987, Cancer research.